Page 79 - Read Online

Page 22 of 23 Casolino et al. Hepatoma Res 2021;7:76 https://dx.doi.org/10.20517/2394-5079.2021.79

85. Silverman IM, Murugesan K, Lihou CF, et al. Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable
alterations in advanced cholangiocarcinoma. J Clin Oncol 2019;37:4080. DOI
86. Cocco E, Schram AM, Kulick A, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med
2019;25:1422-7. DOI PubMed PMC
87. Misale S, Bozic I, Tong J, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat
Commun 2015;6:8305. DOI PubMed PMC
88. Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA
Cancer J Clin 2020;70:125-37. DOI PubMed PMC
89. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med
2015;373:726-36. DOI PubMed PMC
90. Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a
phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234-43. DOI PubMed
91. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles:
results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018;36:536-42. DOI PubMed
92. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020;11:3801. DOI PubMed PMC
93. Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary
tract cancer. JAMA Oncol 2020;6:888-94. DOI PubMed PMC
94. Shen T, Zheng S, Geng L, et al. Experience with anti-PD-1 antibody, camrelizumab, monotherapy for biliary tract cancer patients and
literature review. Technol Cancer Res Treat 2020;19:1533033820979703. DOI PubMed PMC
95. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-
high solid tumors. Clin Cancer Res 2019;25:3753-8. DOI PubMed
96. Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results
from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020;147:2190-8. DOI PubMed
97. Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with
intrahepatic cholangiocarcinoma. Ann Surg Oncol 2016;23:2610-7. DOI PubMed
98. Kitano Y, Yamashita YI, Nakao Y, et al. Clinical significance of PD-L1 expression in both cancer and stroma cells of
cholangiocarcinoma patients. Ann Surg Oncol 2020;27:599-607. DOI PubMed
99. Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene 2020;39:3620-37. DOI
PubMed PMC
100. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite
instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1-10. DOI
PubMed PMC
101. Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with
unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol
2019;4:611-21. DOI PubMed
102. Merck reports topline data for Bintrafusp alfa as second-line monotherapy treatment in biliary tract cancer. Available from:
https://www.merckgroup.com/en/news/bintrafusp-topline-data-biliary-tract-cancer-16-03-2021.html [Last accessed on 16 Nov 2021].
103. Merck statement on phase II study of Bintrafusp alfa in first-line treatment of biliary tract cancer. Available from:
https://www.merckgroup.com/en/news/bintrafusp-alfa-update-23-08-2021.html [Last accessed on 16 Nov 2021].
104. Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or
metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist 2018;23:1407-e136. DOI PubMed
PMC
105. Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor
prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013;58:1992-2000. DOI PubMed
106. Sulpice L, Desille M, Turlin B, et al. Gene expression profiling of the tumor microenvironment in human intrahepatic
cholangiocarcinoma. Genom Data 2016;7:229-32. DOI PubMed PMC
107. Louis C, Edeline J, Coulouarn C. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert
Opin Ther Targets 2021;25:153-62. DOI PubMed
108. Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer
aggressiveness. World J Hepatol 2017;9:455-68. DOI PubMed PMC
109. Martín-Sierra C, Martins R, Laranjeira P, et al. Functional and phenotypic characterization of tumor-infiltrating leukocyte subsets and
their contribution to the pathogenesis of hepatocellular carcinoma and cholangiocarcinoma. Transl Oncol 2019;12:1468-79. DOI
PubMed PMC
110. Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology
2014;59:2397-402. DOI PubMed PMC
111. Zhou G, Sprengers D, Mancham S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex
vivo targeting immune checkpoint molecules. J Hepatol 2019;71:753-62. DOI PubMed
112. Chen Z, Guo P, Xie X, Yu H, Wang Y, Chen G. The role of tumour microenvironment: a new vision for cholangiocarcinoma. J Cell
Mol Med 2019;23:59-69. DOI PubMed PMC
113. Raggi C, Correnti M, Sica A, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated
macrophages. J Hepatol 2017;66:102-15. DOI PubMed PMC